Mydriatics and Mydriolytics

Clinical Ocular Pharmacology

Volumn , Issue , 2008, Pages 113-123

  Portello, Joan K ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878806375     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7576-5.50013-6     Document Type: Chapter

References (65)

1. Allinson RW, Gerber DS, Bieber S, Hodes BL Reversal of mydriasis by dapiprazole. Ann Ophthalmol 1990, 22:131-138.
2. Alster Y, Loewenstein A, Baumwald T, et al. Dapiprazole for patients with night halos after excimer keratectomy. Graefes Arch Clin Exp Ophthalmol 1996, 234(suppl 1):S139-S141.
3. Altman AJ, Albert DM, Fournier GA Cocaine's use in ophthalmology: our 100-year heritage. Surv Ophthalmol 1985, 29:300-306.
4. Anicho UM, Cooper J, Feldman J, et al. The clinical efficacy of Paremyd with and without dapiprazole in subjects with light and dark brown irides. Optom Vis Sci 1999, 76:94-101.
5. Bartlett JD, Classé JG Dapiprazole: will it affect the standard of care for pupillary dilation?. Optom Clin 1992, 2:113-120.
6. Borromeo-McGrail V, Borduik J, Keitel H Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. J Pediatr 1973, 51:1032-1036.
7. Brown MM, Brown GC, Spaeth GL Lack of side effects from topically administered 10% phenylephrine eyedrops. Arch Ophthalmol 1980, 98:487-488.
8. Bucci MG, D'andrea D, Bettini A, De Gregorio M Dapiprazole for the reversal of mydriasis due to tropicamide. Glaucoma 1987, 9:94-98.
9. Cheeks L, Chapman JM, Green K Corneal endothelial toxicity of dapiprazole hydrochloride. Lens Eye Toxicity Res 1992, 9(2):79-84.
10. Connor CG, Campbell JB, Tirey WW The clinical efficacy of Rev-Eyes in reversing the effects of papillary dilation. J Am Optom Assoc 1993, 64:634-636.
11. Cooper J, Feldman JM, Jaanus SD, et al. Pupillary dilation and funduscopy with 1.0% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) versus tropicamide (0.5% or 1.0%) as a function of iris and skin pigmentation, and age. J Am Optom Assoc 1996, 67:669-675.
12. Cremer SA, Thompson HS, Digre KB, et al. Hydroxyamphetamine mydriasis in Horner's syndrome. Am J Ophthalmol 1990, 110:71-76.
13. Doughty MJ, Lyle WM A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. Optom Vis Sci 1992, 69:358-368.
14. Doughty MJ, Lyle W, Trevino R, et al. A study of mydriasis produced by topical phenylephrine 2.5% in young adults. Can J Optom 1988, 50:40-60.
15. Ehinger B A comparative study of the adrenergic nerves to the anterior eye segment of some primates. Z Zellforsch 1971, 116:157-177.
16. Chapter 6. Drug-induced ocular side effects and drug interactions 1989, Lea & Febiger, Philadelphia. F.T. Fraunfelder, S.M. Meyer (Eds.).
17. Fraunfelder FT, Meyer SM Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am J Ophthalmol 1985, 99:362-363.
18. Friedman JR, Whiting DW, Kosmorsky GS, et al. The cocaine test in normal patients. Am J Ophthalmol 1984, 98:808-810.
19. Gambill HD, Olge KN, Kearns TP Mydriatic effect of four drugs determined by pupillograph. Arch Ophthalmol 1967, 77:740-746.
20. Geyer O, Lazar M Allergic blepharoconjunctivitis due to phenylephrine. J Ocular Pharmacol 1988, 4:123-126.
21. Hanna C Tachyphylaxis. Some cardiovascular actions of hydroxyamphetamine and related compounds. Arch Int Pharmacodyn 1960, 128:469-480.
22. Hanna C, Brainard J, Augsburger KD, et al. Allergic dermatoconjunctivitis caused by phenylephrine. Am J Ophthalmol 1983, 95:703-704.
23. Hoffman BB, Lefkowitz RJ Adrenergic receptor antagonists. Goodman and Gilman's the pharmacological basis of therapeutics 1993, McGraw-Hill, New York, Chapter 11. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
24. Hoffman BB, Lefkowitz RJ Catecholamines and sympath-omimetic drugs. Goodman and Gilman's the pharmacological basis of therapeutics 1993, McGraw-Hill, New York, Chapter 10. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
25. Hogan TS, McDaniel DD, Bartlett JD, et al. Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. J Ocular Pharmacol Ther 1997, 13:297-302.
26. Jennings BJ, Sullivan DE The effect of topical 2.5% phenylephrine and 1% tropicamide on systemic blood pressure and pulse. J Am Optom Assoc 1986, 57:382-389.
27. Johnson ME, Molinari JF, Carter J Efficacy of dapiprazole with hydroxyamphetamine hydrobromide and tropicamide. J Am Optom Assoc 1993, 64:629-633.
28. Kamar V, Packer AJ, Choi WW Hypertension following 2.5% phenylephrine ophthalmic drops. Glaucoma 1985, 7:131-132.
29. Krumholz DM, Portello JK, Rosenfield M, Rosenbaum JD Reduced concentrations of tropicamide and phenylephrine in a single solution is effective for pupillary dilation. Optom Vis Sci 1999, 76(suppl):115.
30. Lanche R Systemic reactions to topical epinephrine and phenylephrine. Am J Ophthalmol 1966, 61:95-98.
31. Laties AM, Veleria P, Catanese B, et al. Pharmacokinetics and biochemistry of dapiprazole. Dapiprazole: a new alpha blocking agent in ophthalmology 1987, 7. Kugler Publications, Amsterdam.
32. Lyle WM, Bobier WR Effects of topical anesthetics on phenylephrine-induced mydriasis. Am J Optom Physiol Opt 1977, 54:276-281.
33. Mallen EAH, Gilmartin B, Wolffsohn JS Sympathetic innervation of ciliary muscle and oculomotor function in emmetropic and myopic young adults. Vision Res 2004, 45:1641-1651.
34. Mapstone R Mechanics of pupil block. Br J Ophthalmol 1968, 52:19-25.
35. Mastropasqua L, Carpineto P, Ciancaglini M, et al. Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. Ophthalmic Res 1996, 28:312-318.
36. Meyer SM, Fraunfelder FT Phenylephrine hydrochloride. Ophthalmology 1980, 87:1177-1180.
37. Mitsui Y, Takagi Y Nature of aqueous floaters due to sympath-omimetic mydriatics. Arch Ophthalmol 1961, 65:626-631.
38. Molinari JF, Carter JH, Johnson ME Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field?. Optom Vis Sci 1995, 72:552-556.
39. Molinari JF, Johnson ME, Carter J Dapiprazole. Clinical efficacy for counteracting tropicamide 1%. Optom Vis Sci 1994, 71:319-322.
40. Motameni M, Jaanus SD Pediatric Horner's syndrome. Case report and review. Clin Eye Vis Care 1992, 4:103-107.
41. Munden PM, Kardon RH, Denison CE, et al. Palpebral fissure responses to topical adrenergic drugs. Am J Ophthalmol 1991, 111:706-710.
42. Neufeld AH, Zawistowski KA, Page ED, Bromberg BB Influences on the density of beta adrenergic receptors in the cornea and iris-ciliary body of the rabbit. Invest Ophthalmol 1978, 17:1069-1075.
43. Neuhaus RW, Hepler RS Mydriatic effect of phenylephrine 10% vs. phenylephrine 2.5% (aq). Ann Ophthalmol 1980, 12:1159-1160.
44. Nyman N, Keates EU Effects of dapiprazole on the reversal of pharmacologically induced mydriasis. Optom Vis Sci 1990, 67:705-709.
45. Nyman N, Reich L The effect of dapiprazole on accommodative amplitude in eyes dilated with 0. 5% tropicamide. J Am Optom Assoc 1993, 64:625-628.
46. Chapter 4. St. Louis: Facts and Comparisons Division 2006, Ophthalmic drug facts, Wolters Kluwer Health.
47. Paggiarino DA, Brancato LJ, Newton RE The effect on pupil size and accommodation of sympathetic and parasympatholytic agents. Ann Ophthalmol 1993, 25:244-253.
48. Ponte F, Cillino S, Faranda F, et al. Intraocular dapiprazole for the reversal of mydriasis after cataract extraction with intraocular lens implantation. J Cataract Refract Surg 1991, 17:785-789.
49. Prosdocimo G, De Marco D Intraocular dapiprazole to reverse mydriasis during extracapsular cataract extraction. Am J Ophthalmol 1988, 105:321-322.
50. Ritchie JM, Greene NM Local anesthetics. Goodman and Gilman's the pharmacological basis of therapeutics 1993, McGraw-Hill, New York, Chapter 15. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
51. Rosenfield M Accommodation. The ocular examination. Measurement and findings 1997, 87-121. W. B. Saunders, Philadelphia. K. Zadnik (Ed.).
52. Samantary S, Thomas A Systemic effects of topical phenylephrine. Ind J Ophthalmol 1975, 23:16-17.
53. Semes LP, Bartlett JD Mydriatic effectiveness of hydroxyamphetamine. J Am Optom Assoc 1982, 53:899-904.
54. Smith RB, Everett WG Physiology and pharmacology of local anesthetic agents. Int Ophthalmol Clin 1973, 13:35-43.
55. Solosko D, Smith R Hypertension following 10% phenylephrine ophthalmic. Anesthesiol 1972, 36:187-189.
56. Stephens KG Effect of the sympathetic nervous system on accommodation. Am J Optom Physiol Opt 1985, 62:402-406.
57. The National Registry of Drug-Induced Ocular Side Effects. Accessed May 23, 2006 from. http://piodr.sterling.net.
58. Thompson HS, Menscher JH Adrenergic mydriasis in Horner's syndrome; hydroxyamphetamine test for diagnosis of postganglionic defects. Am J Ophthalmol 1971, 72:472-480.
59. Van Buskirk EM, Bacon DR, Fahrenbach WH Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol 1990, 109:511-517.
60. Weiss DI, Shaffer RN Mydriatic effects of one-eighth percent phenylephrine. Arch Ophthalmol 1962, 68:727-729.
61. Wellwood M, Goresky GV Systemic hypertension associated with topical administration of 2.5% phenylephrine HCl. Am J Ophthalmol 1982, 93:369-374.
62. Wicox CS, Heiser JF, Crowder AM, et al. Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole. Br J Ophthalmol 1995, 79:544-548.
63. Wilensky J, Woodward H Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride. Am J Ophthalmol 1973, 76:156-157.
64. Zeise MM, McDougall BWJ, Bartlett JD, et al. Comparison of efficacy and tolerance between 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) and 0.5% tropicamide combined with 2.5% phenylephrine. J Am Optom Assoc 1996, 67:681-689.
65. Zinn KM Chapter 2. The pupil 1972, Charles C Thomas, Springfield, IL.